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esponsibility of Xi'aAbstract Inosiplex is a compound formulation composed of inosine and p-acetaminobenzoic acid
(PABA) salt of N,N-dimethylamino-2-propanol (DIP). This study was to investigate the clinical plasma
pharmacokinetic properties of DIP and PABA after single and multiple oral doses of inosiplex tablets in
healthy Chinese volunteers. The established LC/MS/MS method for plasma DIP determination had a
linear range of 0.02–10 mg/mL, and the HPLC method for plasma PABA determination had a linear range
of 0.05–40 mg/mL. Linear pharmacokinetic characteristics were found with single oral doses of 0.5, 1.0
and 2.0 g. No obvious accumulation effects were observed for DIP and PABA.
& 2013 Xi’an Jiaotong University. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
The antiviral agent inosiplex is composed of inosine, p-acetamino-
benzoic acid (PABA), and N,N-dimethylamino-2-propanol (DIP) insity. Production and hosting by Elsev
1
5 83271090.
. Ding),
n Jiaotong University.molar ratio of 1:3:3 (Fig. 1). Although little is known about the precise
mechanism of the action of inosiplex, numerous studies have shown its
ability to potentiate certain aspects of the cellular immune response [1]
both in vitro and in vivo. Inosiplex was found to have a broad spectrum
of antiviral activity, including alleviating symptoms of subacute
sclerosing panencephalitis, symptomatic subclinical human papilloma-
virus infection, and cervical condylomata acuminata because of genital
human papillomavirus [2–4]. Inosiplex could also delay the progression
of HIV infection to overt AIDS [5]. In addition, inosiplex has been
employed as an immunoregulating agent for the treatment of
immunopathological disorders, such as rheumatoid arthritis and
alopecia areata [6,7]. However, limited data was published up to
now on the bioassay and pharmacokinetics of inosiplex [8]. Andier B.V. All rights reserved.
Fig. 1 Chemical structures of (A) inosiplex, (B) amantadine (internal
standard for DIP), and (C) paracetamol (internal standard for PABA).
M. Chan et al.388providing an integrated measure of inosiplex pharmacokinetics is of
great importance in rational clinical therapeutic application of inosiplex.
Therefore, endeavor has been done in this work to carry out the plasma
pharmacokinetic studies of inosiplex tablets in Chinese volunteers.
To meet the demands for pharmacokinetic studies, a selective,
sensitive and robust analytical method is highly desirable for each
active component. It was reported that the concentration of inosine
did not increase obviously with dose enhancement and was
maintained in the range of 100–1000 ng/mL in healthy volunteers
[9,10]. Although it has been reported [8,11,12] that PABA is
extensively metabolized to p-aminohippuric acid and p-
acetaminohippuric acid, for they are not pharmacologically as
active as PABA and readily eliminated into the urine, the study
here did not emphasize the determination of inosine, but focused
on the analysis of DIP and the unconjugated PABA in the
biological samples. In this paper, an LC/MS/MS determination
method [13,14] for DIP and an HPLC method for PABA have
been set up, respectively, and the established methods were
applied to plasma pharmacokinetic studies of DIP and PABA in
30 healthy Chinese volunteers after oral administration of inosi-
plex tablets. Meanwhile, the food and gender effects on the
pharmacokinetic properties have been investigated as well. There-
fore, this research is of a great importance on rational and safe
clinical therapeutic application of inosiplex tablets.Fig. 2 Product ions spectra of (A) DIP and (B) amantadine.2. Materials and methods
2.1. Chemicals and reagents
Inosiplex tablets (500 mg/tablet; Batch no. 100202S), inosine,
DIP, and PABA reference standards were supplied by Shenzhen
Salubris Pharmaceuticals Co., Ltd., China. Amantadine (from the
Jiangsu Chia-tai Tianqing Pharmaceutical Co., Ltd., China, Batch
no. 20040905) and paracetamol (from the National Institute for the
Control of Pharmaceutical and Biological Products, China, Batch
no. 10018-200408) were used as the internal reference standards
(IS) for the determination of plasma DIP and PABA, respectively.
Methanol and acetonitrile were chromatographic pure grades and
purchased from Merck, Darmstadt, Germany. Other chemicals
were all of analytical grades. Water was double-distilled and the
mobile phase was ﬁltered through 0.22 μm ﬁlm before use.2.2. Instrumentation
A Finnigan Surveyor system (Thermo Finnigan, San Jose, CA)
containing a Surveyor LC pump, a Surveyor auto-sampler, and a
TSQ Quantum Ultra AM triple-quadrupole tandem mass spectro-
meter with an ion max source was used for DIP determination. The
LC/MS/MS system was operated with the Xcalibur 1.1 software.
The HPLC analysis for PABA was carried out using an Agilent
Liquid Chromatography System series 1100 (Agilent Technolo-
gies, USA), with a binary pump, an auto-sampler, a solvent
degasser and a column oven.2.3. Chromatographic and MS/MS conditions
HPLC separation for DIP was performed on a Phenomenex Luna
5u CN analytical column (250 mm 4.6 mm, 5 μm) at 30 1C with
a mixture of acetonitrile–0.5% formic acid and 0.5% ammonium
acetate solution (75:25, v/v) as a mobile phase which was
delivered at 1 mL/min. Thirty percent of the eluent was split into
the inlet of the MS spectrometer using an electrospray ionization
(ESI) source.
The TSQ Quantum parameters were optimized and set as
following: positive electrospray ionization with spray voltage of
5000 V, capillary temperature of 350 1C, nitrogen sheath gas
pressure of 240 kPa, auxiliary gas pressure of 35 kPa, argon
collision gas pressure of 0.2 Pa and collision energy of 25 eV.
Quantiﬁcations were performed by using selected reaction
Pharmacokinetic study of inosiplex tablets in healthy Chinese volunteers 389monitoring (SRM) with ion transitions of m/z 104.1→71.1 for DIP,
and m/z 152.1→135.1 for amantadine. Fig. 2 shows the full scan
positive ESI product ion mass spectra and the daughter ions
selected for MRM were [M+H-H2O-CH3·]+· for DIP and [M+H-
NH3]
+ for amantadine.Fig. 3 Typical MRM chromatograms of DIP and IS (amantadine) in
human plasma. (A) Blank plasma sample; (B) plasma sample spiked
with 10.0 μg/mL DIP and 4.00 μg/mL amantadine (IS); and (C)
plasma sample 4 h after an oral administration of 1.0 g inosiplex
tablets to a volunteer (DIP 1.01 μg/mL and amantadine 4.00 μg/mL).Plasma PABA was separated on an Agilent HC-C18 analytical
column (150 mm 4.6 mm, 5 μm) with the mobile phase of
methanol–0.2% ammonium acetate and 0.2% acetic acid solution
(15:85, v/v). The UV detection wavelength was chosen at 266 nm.
2.4. Preparation of stock and working standard solutions
Primary stock solutions of DIP and PABA were prepared by
dissolving appropriate amounts of the chemical reference sub-
stances in methanol, which were found to be stable for 30 days
stored at 4 1C. Appropriate dilutions were made in methanol to
produce a series of working standard solutions in the range of
0.2–100 mg/mL and 0.5–400 mg/mL for DIP and PABA, respec-
tively. The amantadine and paracetamol solutions were prepared in
the same way with the concentrations of 4 and 50 mg/mL. All the
working standard solutions were freshly prepared, and stored at
4 1C.
2.5. Sample preparation
A protein precipitation method was employed for the DIP plasma
sample pretreatment. Aliquot of 0.4 mL plasma sample was spiked
with 40 μL of the IS solution (amantadine in methanol, 4.0 mg/mL)
and then protein precipitation was induced by the addition of
0.8 mL acetonitrile and vortex mixing for 1 min. After centrifuga-
tion at 15,000g for 10 min, 10 mL supernatant was injected into the
LC/MS/MS system for the quantiﬁcation of DIP.
Liquid–liquid extraction was used for plasma sample work-up for
the determination of PABA. Aliquot of 0.5 mL plasma sample was
spiked with 50 μL of the IS solution (paracetamol in methanol, 50 mg/
mL) and then mixed with 0.10 mL of hydrochloric acid (2.0 M) for
acidiﬁcation. The mixture was then extracted with 5.0 mL ethyl acetate
by vortex-mixing for 2 min. After centrifugation at 1000g force for
10 min, the organic layer was transferred to a new tube and evaporated
to dryness under a stream of nitrogen. The residual was reconstituted in
0.15 mL of the mobile phase and centrifuged at 15,000g for 10 min
and 20 μL of the supernatant obtained was injected into the HPLC
system for the analysis of PABA.
2.6. Assay validation
The LC/MS/MS and HPLC methods were validated according to
the Food and Drug Administration guidelines for bioanalytical
method validation [15]. Selectivity was performed using six
different sources of blank plasma. They were extracted and
analyzed, and the responses at the retention time of the analytes
and IS were assessed. Calibration curves were created by plotting
the peak area ratios of the corresponding analyte versus the
concentrations. To assess linearity, the coefﬁcient of correlation
(r2) should be more than 0.99 and deviations should be within
715% from nominal concentrations except for the LOQ level, at
which a deviation of 720% is permitted. Accuracy and precision
were determined by assaying ﬁve replicates of quality control
samples at the low, middle and high levels. Accuracy and
precision were calculated in terms of relative error (RE, %) and
relative standard deviation (RSD, %), respectively. The LOQ is
deﬁned as the lowest concentration. The recovery was determined
at three quality control levels by comparing the peak areas
obtained from plasma samples to those from spike-after samples.
To evaluate the matrix effect of DIP, chromatographic peak areas
of DIP from the spike-after protein precipitated samples were
Table 1 Precision and accuracy of the LC/MS/MS method to determine DIP in human plasma (n¼3 days, ﬁve replicates per day).
Spiked concentration (μg/mL) Intra-batch Inter-batch
Mean (μg/mL) RSD(%) (n¼5) Relative error (%) Mean (μg/mL) RSD (%) (n¼15) Relative error (%)
0.0400 0.04247 5.3 6.2 0.04127 8.1 3.1
0.400 0.4043 1.9 1.1 0.4097 4.0 0.9
4.00 3.983 2.2 0.42 4.063 5.0 1.5
Fig. 4 Typical chromatograms of PABA and IS (paracetamol) in human
plasma. (A) Drug-free plasma sample; (B) plasma sample spiked with
PABA (tR¼7.7 min, C¼1.00 μg/mL) and IS (paracetamol, tR¼5.5 min,
C¼5.00 μg/mL); and (C) plasma obtained from a volunteer at 0.5 h after
oral administration of 0.5 g inosiplex with PABA (tR¼7.7 min, C¼2.22
μg/mL) and IS (paracetamol, tR¼5.5 min, C¼5.00 μg/mL).
M. Chan et al.390compared to the neat standards at the quality control concentra-
tions. The variability in matrix factors should be less than 15%.
Long-term storage stability, short-term temperature stability, auto-
sampler rack stability, post-preparative stability, freeze-thaw
stability and stock solution stability of DIP and PABA plasma
samples were also investigated.
2.7. Pharmacokinetic study design
Thirty healthy Chinese volunteers, ranging in age from 30 to 40 years
(3473.3 years), in weight from 50 to 65 kg (60.574.1 kg), and in
height from 150 to 175 cm (164.976.5 cm) were recruited. All
subjects gave their written consent for their participation in the study
after having been informed all aspects of the study, especially the
potential risks. The study protocols were approved by the relevant
Ethical Review Committee in Xijing hospital, Xi'an, China, in
accordance with the principles of the Declaration of Helsinki and the
recommendations of the State Food and Drug Administration of China.
The study was carried out with an open-label, randomized, three
periods design. Subjects were divided into three groups with male
and female equally assigned in each group (Groups I, II, and III).During the ﬁrst period, Groups I–III were given a single oral dose
of 0.5, 1.0 and 2.0 g inosiplex, with 250 mL of water after an over-
night 12 h fast. The food effect study was conducted with Group II
after a 7-day wash-out period and a single dose of 1.0 g inosiplex
tablets was administered immediately following an FDA deﬁned
high fat breakfast consumed within 30 min. In the third period,
multiple oral doses (1.0 g inosiplex t.i.d.) were administered to
Group II for 7 consecutive days except for the 7th day with only a
morning dose after a 7-day wash-out period. Venous blood
samples each of 4 mL were collected in heparinized tubes at 0,
5, 10, 30, 45, 60, 90, 120, 180, 240, 360, 480, 720, and 1440 min,
after dosing and on the 7th day for multiple doses. Venous blood
samples were also collected prior to the morning dose (0 h) on
days 4, 5, and 6 to afﬁrm the steady states of plasma concentra-
tions of DIP and PABA. All plasma samples were separated
immediately by centrifugation at 1000g force for 10 min at 4 1C
and stored at −80 1C until analysis.2.8. Pharmacokinetic analysis
The plasma pharmacokinetic parameters including Cmax, Tmax, t1/2
and AUC were estimated by standard non-compartmental methods
using a DAS2.0 software for both DIP and PABA. An analysis of
variance (ANOVA) was performed for Cmax and AUC0−τ after
natural logarithmic transformation using a general linear model
procedure for randomized crossover design to evaluate the effects
of periods, food, and subjects at the signiﬁcance level (α) of 0.05.
The Wilcoxon signed rank test was used for the non-parametric
analysis to determine differences in Tmax. Effects were considered
statistically signiﬁcant if the probability obtaining the calculated F
test was ≤0.05.3. Results and discussion
3.1. Analysis of DIP
Method development for the analysis of DIP in plasma began with
the optimization of chromatographic conditions including column
type and mobile phase composition. The feasibility of various
mixtures of solvents, such as acetonitrile and methanol, using
different buffers, such as ammonium acetate, ammonium formate
and formic acid with various pH ranging from 3.0 to 7.0, along
with altered ﬂow-rates was tested for optimum chromatographic
retention of the analytes and IS. Finally, a Phenomenex Luna CN
(250 mm 4.6 mm, 5 μm) column with a mobile phase consisting
of 75 volumes of acetonitrile and 25 volumes of 0.5% formic acid
and 0.5% ammonium acetate solution was selected for the
separation since good chromatographic resolution and symmetrical
peak shapes of the analytes were obtained. They were also
Table 2 Precision and accuracy of the HPLC-UV method to determine PABA in human plasma (n¼3 days, ﬁve replicates per day).
Spiked concentration
(μg/mL)
Intra-batch Inter-batch
Mean (μg/mL) RSD (%) (n¼5) Relative error (%) Mean (μg/mL) RSD (%) (n¼15) Relative error (%)
0.100 0.1117 3.0 11.7 0.1107 5.7 10.2
2.00 2.028 1.3 1.4 2.016 2.0 0.4
20.0 18.74 1.4 6.3 18.77 1.2 6.4
Fig. 5 The mean plasma concentration–time proﬁles of (A) DIP and (B)
PABA in healthy volunteers (n¼10) after a single oral administration of
0.5, 1.0, and 2.0 g and multiple oral doses of 1.0 g inosiplex tablets.
Pharmacokinetic study of inosiplex tablets in healthy Chinese volunteers 391compatible with the determination of the analytes by positive
electrospray ionization MS detection.
Mass spectrometric conditions were optimized so as to achieve
maximum and stable responses of the parent and the major product
ions of the analytes. The predominately protonated molecule ions
were obtained by the positive ESI scan at m/z 104.1 and 152.1 for
DIP and amantadine, respectively. They were apt to form major
product ions at m/z 71.1 and 135.1 with the optimum collision
energies of 25 and 22 eV, respectively.
Fig. 3 shows the typical chromatograms of drug-free plasma, drug-
free plasma spiked with DIP and the IS, and plasma sample from a
volunteer after oral administration. No interference from endogenous
substances with analytes or the IS was detected. The calibration curves
of DIP in human plasma were linear in the concentration range of
0.02–10 μg/mL with correlation coefﬁcient values 40.995. The LOQ
for plasma DIP was 0.02 μg/mL. Table 1 summarizes the intra- and
inter-batch precision and accuracy for DIP. It can be seen that the RSD
values were less than 8.1% and the RE values were all within76.2%.
Mean extraction recoveries were 89.073.6%, 96.073.7% and
103.372.0% at the concentrations of 0.04, 0.4 and 4 μg/mL,
respectively. Average matrix effect values obtained varied from
95.7% to 96.9%, which were found to be within the acceptable limit.
The stock solution was stable for at least 30 days at 4 1C. The stability
experiment conﬁrmed that DIP plasma samples were stable for over 60days when stored at −20 1C and through three freeze-thaw cycles. The
worked out plasma samples were stable for at least 24 h at 4 1C.
3.2. Analysis of PABA
The determination of PABA in plasma has been investigated before
by our and other groups [16–18]. Fig. 4 shows the typical
chromatograms of blank plasma, spiked plasma sample with PABA
and the IS, and the plasma sample from a volunteer after oral
administration. No signiﬁcant interference from endogenous sub-
stances was observed at the retention time of PABA or IS. The
calibration curves were linear over the concentration range of 0.05–
40.0 μg/mL and the LOQ was 0.05 μg/mL. Table 2 summarizes the
intra- and inter-batch precision and accuracy for PABA. It can be
seen that the RSD values were less than 5.7% and the RE values were
all within711.7%. Mean values of absolute recoveries for PABA at
0.10, 2.00 and 20.0 μg/mL were 101.873.3%, 104.375.0% and
111.073.0%, respectively. The stock solution was stable for at least
30 days at 4 1C. The stability experiment conﬁrmed that PABA
plasma samples were stable for over 60 days when stored at −20 1C
and through three freeze-thaw cycles. The worked out plasma
samples were stable for at least 24 h at 4 1C.3.3. Pharmacokinetic application
All 30 subjects completed the pharmacokinetic study. The mean
plasma concentration–time proﬁles of DIP and PABA after a
single oral dose of 0.5, 1.0 and 2.0 g inosiplex tablets, and at
steady-state after multiple oral doses of 1.0 g inosiplex tablets are
shown in Fig. 5. The pharmacokinetics parameters are shown in
Table 3. Linear pharmacokinetics was found for both DIP and
PABA based on these results. The plasma concentrations of DIP
and PABA reached steady-state at days 4–7 with the average
minimum concentration of DIP as 0.7770.18 μg/mL and PABA
as 0.0970.02 μg/mL before the morning dose. The food effect
study demonstrated that the food intake had no remarkable effects
on the absorption of DIP, but led to signiﬁcant decrease in the
bioavailability of PABA with the reduction of the AUC of about
13%. This might be attributed to the reason that the food intake
changes the pH values in gastric ﬂuid, affects gastric emptying,
and subsequently inhibits the absorption of the acidic compound,
PABA. No signiﬁcant difference was found between the pharma-
cokinetic parameters after single oral dose of 1.0 g inosiplex
tablets and those at the steady-state. Therefore, there was no
obvious accumulation when inosiplex tablets were orally given
t.i.d., repeatedly. The results of ANOVA for assessment of sub-
jects indicated that no signiﬁcant differences in Cmax, AUC0−τ, and
AUC0−∞ were found between the male and female groups. The
obvious tmax differences between 1 g group and 0.5 g, 2 g groups
may be due to the fact that the subjects used for the 1 g single and
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M. Chan et al.392steady-state studies were different from the subjects that had taken
part in the 0.5 g and 2.0 g single dose studies.
The methods were also utilized for the urinary excretion studies
of DIP and PABA. The DIP accumulate urinary excretion rates
(0–24 h) for 0.5, 1.0 and 2.0 g dose groups were 32.4721.4%,
38.4710.7%, and 29.1715.9%, respectively, while for PABA
were 12.477.4%, 29.9714.3%, and 15.8711.2%, respectively.4. Conclusion
The LC/MS/MS and HPLC-UV methods have been set up for the
pharmacokinetic study of inosiplex tablets in healthy Chinese
volunteers. The established LC/MS/MS and HPLC-UV methods
were sensitive and selective for plasma DIP and PABA determina-
tion, respectively, and suitable for the pharmacokinetic study of
inosiplex tablets. The pharmacokinetic characteristics found pro-
vide a useful reference for the rational and safe clinical therapeutic
application of inosiplex tablets from both the dosage regimens and
the therapeutic drug monitoring point of views.
Acknowledgments
This work was ﬁnancially supported by the Fundamental Research
Funds for the Central Universities (Grant no. JKP2011008), the
Qing Lan Project, and the Program for New Century Excellent
Talents in University (Grant no. NCET-10-0816).
References
[1] A. Morin, J.J. Ballet, A recent overview on in vitro and in vivo
immunological activities of methisoprinol, Allergol. Immunopath. 10
(1982) 109–114.
[2] G.G. Gascon, Randomized treatment study of inosiplex versus
combined inosiplex and intraventricular interferon-alpha in subacute
sclerosing panencephalitis (SSPE): international multicenter study,
J. Child Neurol. 18 (12) (2003) 819–827.
[3] S.K. Tay, Efﬁcacy of inosine pranobex oral therapy in subclinical
human papillomavirus infection of the vulva: a randomized double-
blinded placebo controlled study, Int. J. STD AIDS (1996)
276–280.
[4] S. Georgala, A. Katoulis, A. Befon, et al., Oral inosiplex in the
treatment of cervical condylomata acuminata: a randomized placebo-
controlled trial, BJOG 113 (2006) 1088–1091.
[5] C.De Simone, G. Famularo, S. Tzantzoglou, et al., Inosine pranobex
in the treatment of HIV infection: a review, Int. J. Immunopharmacol.
13 (Suppl. 1) (1991) S19–S27.
[6] M. Brzeski, R. Madhok, J.A. Hunter, et al., Randomised, double
blind, placebo controlled trial of inosine pranobex in rheumatoid
arthritis, Ann. Rheum. Dis. 49 (1990) 293–295.
[7] S. Georgala, A.C. Katoulis, A. Befon, et al., Inosiplex for treatment of
alopecia areata: a randomized placebo-controlled study, Acta Derm.
Venereol. 86 (2006) 422–424.
[8] D.G. Streeter, E.H. Pfadenhauer, Inosiplex: metabolism and excretion
of the dimethylaminoisopropanol and p-acetamidobenzoic acid com-
ponents in rhesus monkeys, Drug Metab. Dispos. 12 (1984) 199–203.
[9] D. Farthing, D. Sica, T. Gehr, et al., An HPLC method for
determination of inosine and hypoxanthine in human plasma from
healthy volunteers and patients presenting with potential acute cardiac
ischemia, J. Chromatogr. B 854 (2007) 158–164.
[10] L. Liu, J.F. Song, P.F. Yu, et al., A novel electrochemical sensing
system for inosine and its application for inosine determination in
pharmaceuticals and human serum, Electrochem. Commun. 8 (2006)
1521–1526.
Pharmacokinetic study of inosiplex tablets in healthy Chinese volunteers 393[11] K. Chan, J.O. Miners, D.J. Birkett, Direct and simultaneous high-
performance liquid chromatographic assay for the determination of
p-aminobenzoic acid and its conjugates in human urine, J. Chroma-
togr. 426 (1998) 103–109.
[12] L.H. Wang, W.S. Huang, H.M. Tai, Simultaneous determination of p-
aminobenzoic acid and its metabolites in the urine of volunteers,
treated with p-aminobenzoic acid sunscreen formulation, J. Pharm.
Biomed. Anal. 12 (2007) 1430–1436.
[13] X.J. Li, Y.T. Sun, L. Yin, et al., Quantitation of bivalirudin, a novel
anticoagulant peptide, in human plasma by LC–MS/MS: method
development, validation and application to pharmacokinetics, J.
Pharm. Anal. 3 (1) (2013) 1–8.
[14] S.R. Polagani, N.R. Pilli, R. Gajula, et al., Simultaneous determina-
tion of atorvastatin, metformin and glimepiride in human plasma by
LC–MS/MS and its application to a human pharmacokinetic study, J.
Pharm. Anal. 3 (1) (2013) 9–19.[15] V.P. Shah, K.K. Midha, J.W. Findlay, et al., Bioanalytical method
validation—a revisit with a decade of progress, Pharm. Res. 17
(2000) 1551–1557.
[16] M. Mirzaei, M. Khayat, A. Saeidi, Determination of para-
aminobenzoic acid (PABA) in B-complex tablets using the multi-
variate curve resolution- alternating least squares (MCR–ALS)
method, Sci. Iran. C 19 (2012) 561–564.
[17] R.J. O'kruk, M.A. Adams, R.B. Philp, Rapid and sensitive determina-
tion of acetylsalicylic acid and its metabolites using reversed-phase
high-performance liquid chromatography, J. Chromatogr. B 310
(1984) 343–352.
[18] X.T. Que, Y. Ding, T.J. Hang, et al., Pharmacokinetics of inosiplex
tablets in healthy Chinese volunteers, Chin. J. New. Drugs Clin. Rem.
10 (2010) 738–742.
